menu
    • menu

    Company profile for ABM Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ABM is an innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer. It was founded in 2015 by a group of biotech and pharmaceutical industry veterans with more than 20 years of experience in the development of neurological drugs and enterprise management from...
    ABM is an innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer. It was founded in 2015 by a group of biotech and pharmaceutical industry veterans with more than 20 years of experience in the development of neurological drugs and enterprise management from North America. Since establishment, ABM is building its broad proprietary pipeline internally to construct a brain medicine R&D platform through collaborations with CROs and partners

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ABM TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    Suite 809,780 Cailun Rd, Zhangjiang, Pudong, Shanghai
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.abmtx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA
    ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA

    26 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abm-therapeutics-abm-1310-granted-fast-track-designation-by-the-fda-following-orphan-drug-designation-301937168.html

    PR NEWSWIRE
    26 Sep 2023
    Share Share
    ABM Therapeutics begins patient dosing in phase I study of ABM-1310
    ABM Therapeutics begins patient dosing in phase I study of ABM-1310

    04 Sep 2023

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=161323&sid=2

    PHARMABIZ
    04 Sep 2023
    Share Share
    ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310
    ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310

    01 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abm-therapeutics-announces-first-patient-dosed-in-phase-i-study-of-abm-1310-in-patients-with-braf-v600-in-relapsed-and-drug-resistant-primary-malignant-brain-tumors-301914312.html

    PR NEWSWIRE
    01 Sep 2023
    Share Share
    ABM Therapeutics doses first patient in Phase I solid tumours trial
    ABM Therapeutics doses first patient in Phase I solid tumours trial

    05 May 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/abm-first-patient-solid-tumours/

    CLINICAL TRIALS ARENA
    05 May 2023
    Share Share
    ABM Announces First Patient Dosed in pHI Trial of MEK Inhibitor for Solid Tumor
    ABM Announces First Patient Dosed in pHI Trial of MEK Inhibitor for Solid Tumor

    04 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abm-announces-first-patient-dosed-in-phase-i-clinical-trial-of-mek-inhibitor-for-solid-tumor-301813371.html

    PR NEWSWIRE
    04 May 2023
    Share Share
    ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310
    ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310

    30 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/abm-therapeutics-receives-ind-approval-in-china-for-braf-inhibitor-abm-1310-301433495.html

    PRNEWSWIRE
    30 Nov 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search